Cinctive Capital Management LP Has $469,000 Holdings in Glaukos Corporation $GKOS

Key Points

• Cinctive Capital Management LP has decreased its holdings in Glaukos Corporation (GKOS) by 53.7%, reducing its shares to 4,765, valued at approximately $469,000.
• Despite this, Bessemer Group Inc. increased its stake by 133.9%, indicating mixed institutional investor sentiment towards Glaukos.
• Glaukos reported earnings per share of ($0.24), beating estimates, while revenue surged 29.7% year-over-year to $124.12 million.

Cinctive Capital Management LP lessened its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 53.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 4,765 shares of the medical instruments supplier's stock after selling 5,516 shares during the period. Cinctive Capital Management LP's holdings in Glaukos were worth $469,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. State of Wyoming boosted its stake in Glaukos by 2.3% in the 4th quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock worth $487,000 after purchasing an additional 72 shares during the period. Stifel Financial Corp raised its stake in Glaukos by 2.6% during the 4th quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock valued at $651,000 after purchasing an additional 111 shares during the period. Valeo Financial Advisors LLC lifted its holdings in shares of Glaukos by 1.5% in the first quarter. Valeo Financial Advisors LLC now owns 7,817 shares of the medical instruments supplier's stock valued at $769,000 after purchasing an additional 117 shares in the last quarter. LVW Advisors LLC boosted its position in shares of Glaukos by 5.9% in the first quarter. LVW Advisors LLC now owns 2,408 shares of the medical instruments supplier's stock worth $237,000 after buying an additional 135 shares during the period. Finally, Bessemer Group Inc. boosted its position in shares of Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 158 shares during the period. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Up 0.0%

Shares of Glaukos stock traded up $0.01 during trading on Thursday, hitting $87.53. 786,151 shares of the stock traded hands, compared to its average volume of 630,803. The stock has a market cap of $5.02 billion, a P/E ratio of -53.05 and a beta of 0.77. The company has a fifty day moving average price of $93.90 and a two-hundred day moving average price of $96.08. Glaukos Corporation has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company's revenue for the quarter was up 29.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GKOS shares. BTIG Research reissued a "buy" rating and set a $118.00 price target on shares of Glaukos in a research report on Wednesday. William Blair raised Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Zacks Research downgraded Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Wells Fargo & Company increased their price target on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, UBS Group raised their price target on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $124.83.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.